Compare NTRA & VLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTRA | VLTO |
|---|---|---|
| Founded | 2003 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Electrical Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0B | 24.5B |
| IPO Year | 2015 | N/A |
| Metric | NTRA | VLTO |
|---|---|---|
| Price | $229.36 | $99.91 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 9 |
| Target Price | ★ $238.20 | $113.25 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 11-06-2025 | 02-03-2026 |
| Dividend Yield | N/A | ★ 0.51% |
| EPS Growth | N/A | ★ 12.64 |
| EPS | N/A | ★ 3.65 |
| Revenue | $2,116,676,000.00 | ★ $5,452,000,000.00 |
| Revenue This Year | $33.18 | $8.28 |
| Revenue Next Year | $16.81 | $5.74 |
| P/E Ratio | ★ N/A | $27.77 |
| Revenue Growth | ★ 38.17 | 6.15 |
| 52 Week Low | $125.38 | $83.87 |
| 52 Week High | $246.90 | $110.11 |
| Indicator | NTRA | VLTO |
|---|---|---|
| Relative Strength Index (RSI) | 52.01 | 46.07 |
| Support Level | $227.89 | $99.47 |
| Resistance Level | $237.04 | $101.75 |
| Average True Range (ATR) | 5.07 | 1.56 |
| MACD | -1.57 | 0.05 |
| Stochastic Oscillator | 49.47 | 42.89 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Veralto is a diversified industrial firm organized into two segments, water quality as well as product quality and innovation. The water quality segment offers water analytics and water treatment solutions, while the product quality and innovation segment offers coding, packaging, and color solutions for consumer packaged goods and pharmaceuticals. Headquartered in Waltham, Massachusetts, the company has around 17,000 employees. Veralto generated approximately $5.2 billion in revenue in 2024.